Your browser doesn't support javascript.
loading
The immune effects of rituximab on dendritic cells derived from patients with primary immune thrombocytopenia / 中华血液学杂志
Chinese Journal of Hematology ; (12): 207-210, 2012.
Article in Chinese | WPRIM | ID: wpr-359529
ABSTRACT
<p><b>OBJECTIVE</b>To explore the changes of surface antigen and function of rituximab on dendritic cells derived from patients with Primary immune thrombocytopenia (ITP) to further understand the effective mechanism of immunotherapy.</p><p><b>METHODS</b>The peripheral blood mononuclear cells (PBMCs) were isolated from remission patients with ITP before and after low-dose rituximab infusion, and the PMNCs were stimulated for 5 days by rhGM-CSF and rhlL-4 in 5% CO2 air at 37°C incubator. Then all of DCs were cultured with TNF-α for 48 hours. The morphology of DCs was monitored under inverted microscope daily, and the surface antigens of the DCs were analysed by flow cytometry, meanwhile the levels of IL-12p70 and TGF-β1 in supernatants were detected by ELISA, mix lymphocyte reaction was performed by MTT assay.</p><p><b>RESULTS</b>(1) Rituximab-treated-DCs showed no obvious tree-like protruding compared with untreated-DCs. The former cells were small and most of nucleus were centric. (2) The expressions of HLA-DR, CD80, CD83 and CD86 on rituximab-treated-DCs \[56.37 ± 3.95)%, (36.41 ± 2.82)%, (30.45 ± 4.61)% and (41.98 ± 4.17)%, respectively\] were significantly lower than those untreated-DCs \[(73.71 ± 7.61)%, (55.14 ± 7.30)%, (80.91 ± 7.09)% and (59.03 ± 3.43)%, respectively\](all P < 0.05), the concentration of IL-12p70 was significantly lower, \[(66.87 ± 4.29)% vs (50.17 ± 14.52)%\], while that of TGF-β1 \[(9.70 ± 0.31)%\] higher than the untreated-DCs \[(2.70 ± 0.36)%\] (P < 0.05). (3) The abilities to activate T cells proliferation of rituximab-treated-DCs reduced compared with untreated-DCs.</p><p><b>CONCLUSION</b>The surface antigen of ITP-DCs and the concentration of IL-12p70 reduced after the low-dose rituximab infusion. The abilities to activate T cells proliferation reduced while the concentration of TGF-β1 increased. Rituximab may achieve its therapeutic effect on ITP by downregulating the immunoreactivity of DCs.</p>
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Thrombocytopenia / Dendritic Cells / Lymphocyte Activation / T-Lymphocytes / Cells, Cultured / Interleukin-12 / Bodily Secretions / Cell Biology / Therapeutic Uses / Cell Proliferation Limits: Female / Humans / Male Language: Chinese Journal: Chinese Journal of Hematology Year: 2012 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Thrombocytopenia / Dendritic Cells / Lymphocyte Activation / T-Lymphocytes / Cells, Cultured / Interleukin-12 / Bodily Secretions / Cell Biology / Therapeutic Uses / Cell Proliferation Limits: Female / Humans / Male Language: Chinese Journal: Chinese Journal of Hematology Year: 2012 Type: Article